Evidence map›Paper›PMID 26202228›Full record

ArticleJournal of virology2015

A Higher Frequency of NKG2A+ than of NKG2A- NK Cells Responds to Autologous HIV-Infected CD4 Cells irrespective of Whether or Not They Coexpress KIR3DL1.

Irene Lisovsky, Gamze Isitman, Rujun Song, Sandrina DaFonseca, Alexandra Tremblay-McLean, Bertrand Lebouché, Jean-Pierre Routy, Julie Bruneau, Nicole F Bernard

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Irene LisovskyResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Gamze IsitmanResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Rujun SongResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Sandrina DaFonsecaResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Alexandra Tremblay-McLeanResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Bertrand LebouchéResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada Chronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada Department of Family Medicine, McGill University, Montreal, Quebec, Canada.
Jean-Pierre RoutyDivision of Experimental Medicine, McGill University, Montreal, Quebec, Canada Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
Julie BruneauDepartment of Family Medicine, Université de Montréal, Montreal, Quebec, Canada Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Nicole F BernardResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada Chronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada Division of Clinical Immunology, McGill University Health Centre, Montreal, Quebec, Canada nicole.bernard@mcgill.ca.
McGill University Health Centre · CACentre Hospitalier de l’Université de Montréal · CAMcGill University · CARoyal Victoria Regional Health Centre · CA

Funding

Canadian Institutes of Health Research MOP 123800
6 · The paper itself

Abstract

unlabelledEpidemiological and functional studies implicate NK cells in HIV control. However, there is little information available on which NK cell populations, as defined by the inhibitory NK cell receptors (iNKRs) they express, respond to autologous HIV-infected CD4(+) (iCD4) T cells. NK cells acquire antiviral functions through education, which requires signals received from iNKRs, such as NKG2A and KIR3DL1 (here, 3DL1), engaging their ligands. NKG2A interacts with HLA-E, and 3DL1 interacts with HLA-A/B antigens expressing the Bw4 epitope. HIV-infected cells downregulate HLA-A/B, which should interrupt negative signaling through 3DL1, leading to NK cell activation, provided there is sufficient engagement of activating NKRs. We examined the functionality of NK cells expressing or not NKG2A and 3DL1 stimulated by HLA-null and autologous iCD4 cells. Flow cytometry was used to gate on each NKG2A(+)/NKG2A(-) 3DL1(+)/3DL1(-) (NKG2A(+/-) 3DL1(+/-)) population and to measure the frequency of all possible combinations of CD107a expression and gamma interferon (IFN-γ) and CCL4 secretion. The highest frequency of functional NK cells responding to HLA-null cell stimulation was the NKG2A(+) 3DL1(+) NK cell population. The highest frequencies of functional NK cells responding to autologous iCD4 cells were those expressing NKG2A; coexpression of 3DL1 did not further modulate responsiveness. This was the case for the functional subsets characterized by the sum of all functions tested (total responsiveness), as well as by the trifunctional CD107a(+) IFN-γ(+) CCL4(+), CD107a(+) IFN-γ(+), total CD107a(+), and total IFN-γ(+) functional subsets. These results indicate that the NKG2A receptor has a role in NK cell-mediated anti-HIV responses. IMPORTANCE: HIV-infected CD4 (iCD4) cells activate NK cells, which then control HIV replication. However, little is known regarding which NK cell populations iCD4 cells stimulate to develop antiviral activity. Here, we examine the frequency of NK cell populations, defined by the presence/absence of the NK cell receptors (NKRs) NKG2A and 3DL1, that respond to iCD4 cells. NKG2A and 3DL1 are involved in priming NK cells for antiviral functions upon encountering virus-infected cells. A higher frequency of NKG2A(+) than NKG2A(-) NK cells responded to iCD4 cells by developing antiviral functions such as CD107a expression, which correlates with NK cell killing, and secretion of gamma interferon and CCL4. Coexpression of 3DL1 on the NKG2A(+) and NKG2A(-) NK cells did not modulate responses to iCD4 cells. Understanding the mechanisms underlying the interaction of NK cells with iCD4 cells that lead to HIV control may contribute to developing strategies that harness NK cells for preventing or controlling HIV infection.

Indexed as

HIV-1AutoantigensCD4-Positive T-LymphocytesHIV InfectionsHLA AntigensHomozygoteHost-Pathogen InteractionsHumansIn Vitro TechniquesK562 CellsKiller Cells, NaturalLigandsNK Cell Lectin-Like Receptor Subfamily CReceptors, KIR3DL1AutoantigensHLA AntigensKIR3DL1 protein, humanKLRC1 protein, humanLigandsNK Cell Lectin-Like Receptor Subfamily CReceptors, KIR3DL1

Identifiers

PMID26202228
PMCPMC4577891
OpenAlexW1602245252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.